There are hundreds of ways doxorubicin cardiotoxicity can be treated or prevented. What is needed is not another way of preventing cardiotoxicity, but a reason for oncologists to use the cardioprotective drug. The historical evidence suggests that only a drug that is both anticancer AND cardioprotective will cause a change in standard of care.
One other factor this is very important and that is any new cardioprotective drug has to have protectable IP on it. Without IP nobody will pay for the large Phase 3 trial(s) required to change clinical guidelines. If some treatment is not on the guidelines then it won't be used.
RAC Price at posting:
$1.18 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)